Evidence map›Paper›PMID 30221792›Full record

ArticleJournal of veterinary internal medicine2018

Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis.

Charlotte A Easton-Jones, John E Madigan, Samantha Barnum, Lara K Maxwell, Sandra D Taylor, Terry Arnesen, Nicola Pusterla

Open access · goldAbstract readClinical Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Charlotte A Easton-JonesWillian R Pritchard Veterinary Medical Teaching Hospital, University of California Davis, California.ORCID http://orcid.org/0000-0002-4663-6982
John E MadiganDepartment of Medicine and Epidemiology, University of California, Davis, California.
Samantha BarnumDepartment of Medicine and Epidemiology, University of California, Davis, California.
Lara K MaxwellDepartment of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, Oklahoma.
Sandra D TaylorDepartment of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, IN.
Terry ArnesenStillwater Equine Veterinary Clinic, Stillwater, Minnesota.
Nicola PusterlaDepartment of Medicine and Epidemiology, University of California, Davis, California.
University of California, Davis · USOklahoma State University · USPurdue University West Lafayette · USStillwater (Canada) · CAVeterinary Medical Teaching Hospital · US

Funding

University of California, Davis Center for Equine Health with funds provided by the State of California satellite wagering fund and contributions by private donors.
6 · The paper itself

Abstract

backgroundEquine herpesvirus-5 is commonly isolated from the lungs of horses with EMPF, suggesting an etiological link. Valacyclovir is used empirically to treat EMPF; however, no data is available concerning its impact on EHV-5 viral kinetics.

objectivesTo determine the effect of oral administration of valacyclovir on EHV-5 viral load measured by qPCR in blood, nasal secretions (NS) and BALF in horses with EMPF. ANIMALS: Six horses diagnosed with EMPF.

methodsA prospective clinical trial was performed. Horses received 10 days of PO administered valacyclovir (loading dose 30 mg/kg, maintenance dose 20 mg/kg). Blood, NS, and BALF were collected for EHV-5 viral kinetics analyses during treatment. Blood and NS were collected every other day. BALF was collected on day 0 and day 10.

resultsThere was no statistical difference in median EHV-5 viral load between day 0 and day 10 for all samples tested. In blood median EHV-5 viral load was 7676 (range 575-39 781) on day 0 and 6822 (range 1136-18 635) glycoprotein B (gB) gene copies per million cells on day 10. For NS median EHV-5 viral load was 2.944 × 10 CONCLUSIONS AND CLINICAL IMPORTANCE: Valacyclovir might not be an effective short-term antiviral treatment but efficacy in treatment of EMPF is unknown.

Indexed as

GammaherpesvirinaeAnimalsAntiviral AgentsBronchoalveolar Lavage FluidDNA, ViralDose-Response Relationship, DrugFemaleHerpesviridae InfectionsHorse DiseasesHorsesMalePulmonary FibrosisValacyclovirVirus ReplicationAntiviral AgentsDNA, ViralValacycloviranti-viral drugsherpesvirusinterstitial pneumoniaqPCR

Identifiers

PMID30221792
PMCPMC6189341
OpenAlexW2891157983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.